What one share of Zura Bio holds
We are a clinical-stage biotechnology company developing novel and differentiated medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with significant unmet medical need.
Zura Bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.80 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.61 |
| Cash and investments | $2.15 |
| Book value | $2.07 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$2.09 | — | — | — | $1.36 |
| 2024 | — | −$0.60 | $0.00 | −$0.38 | — | $2.25 |
| 2025 | — | −$1.06 | $0.00 | −$0.69 | — | $1.38 |
Common questions about Zura Bio
How much does one share of Zura Bio earn?
Over the last 12 months, Zura Bio lost $0.80 for each share.
Does Zura Bio pay a dividend?
Zura Bio didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Zura Bio’s book value per share?
Zura Bio’s book value is $2.07 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Zura Bio have?
Each share of Zura Bio has $2.15 of cash and investments, as of June 30, 2026.
What is Zura Bio’s free cash flow per share?
−$0.61 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.